{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:20:17Z","timestamp":1789086017900,"version":"build-2803163510"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Blocking enzymatic activity of cluster of differentiation 39 (CD39) with IPH5201 may promote antitumor immunity by increasing immunostimulatory ATP and reducing immunosuppressive adenosine levels in the tumor microenvironment. This first-in-human, phase 1 study evaluated IPH5201 as monotherapy or in combination with durvalumab (anti\u2013PD-L1) in patients with advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>The study consisted of two consecutive dose-escalation parts: IPH5201 monotherapy (100, 300, 1,000, and 3,000 mg) every 3 weeks and IPH5201 (300, 1,000, and 3,000 mg) + durvalumab 1,500 mg every 3 weeks. The primary endpoint was to evaluate safety and tolerability. Secondary endpoints included antitumor activity, pharmacokinetics, and immunogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 38 patients received IPH5201 monotherapy and 19 received IPH5201 + durvalumab, with a median duration of follow-up of 7.6 months (range, 1.0\u201323.7). The most common cancer types were pancreatic (42.1%), non\u2013small cell lung (19.3%), and colorectal (17.5%) cancers. The most common treatment-related adverse events were infusion-related reactions and fatigue. There were no adverse event\u2013related deaths, and the maximum tolerated dose was not reached. Overall, 23\/57 patients (40.4%) had stable disease as their best overall response. IPH5201 exhibited a linear pharmacokinetic profile and an estimated terminal half-life of 8 to 9 days at higher doses. On-treatment tumor biopsies revealed decreased CD39 ATPase activity in 5\/7 patients, including all evaluable patients receiving the maximum dose of IPH5201 3,000 mg every 3 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>IPH5201 as monotherapy, or in combination with durvalumab, was well tolerated at pharmacologically active doses that induced reduction of intratumoral CD39 enzymatic activity and showed preliminary evidence for disease stabilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The adenosine pathway is a source of emerging targets in cancer immunotherapy. IPH5201 is a mAb that targets the adenosine pathway by blocking human CD39 enzymatic activity. In this first-in-human, phase 1 study, IPH5201 as monotherapy or in combination with durvalumab was well tolerated with a manageable safety profile in patients with advanced solid tumors. Preliminary evidence for disease stabilization and reduction of tumoral CD39 enzymatic activity were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0361","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:36:53Z","timestamp":1756899413000},"page":"1690-1700","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7608-0380","authenticated-orcid":false,"given":"John","family":"Powderly","sequence":"first","affiliation":[{"name":"1Carolina BioOncology Institute, Huntersville, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2521-7540","authenticated-orcid":false,"given":"Martina","family":"Imbimbo","sequence":"additional","affiliation":[{"name":"2Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University Hospital, Lausanne, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-5351","authenticated-orcid":false,"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[{"name":"3Institut Bergoni\u00e9, Bordeaux, France."},{"name":"4Faculty of Medicine, University of Bordeaux, Bordeaux, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3923-5160","authenticated-orcid":false,"given":"Patricia","family":"Martin-Romano","sequence":"additional","affiliation":[{"name":"5Gustave Roussy Cancer Center, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0944-7418","authenticated-orcid":false,"given":"Meredith","family":"McKean","sequence":"additional","affiliation":[{"name":"6Sarah Cannon Research Institute, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5856-4082","authenticated-orcid":false,"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[{"name":"7Vall d\u2019Hebron University Hospital, and Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2957-4414","authenticated-orcid":false,"given":"Eduardo","family":"Casta\u00f1\u00f3n Alvarez","sequence":"additional","affiliation":[{"name":"8Universidad de Navarra, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-1126","authenticated-orcid":false,"given":"Benedito A.","family":"Carneiro","sequence":"additional","affiliation":[{"name":"9Legorreta Cancer Center, Brown University, and Lifespan Cancer Institute, Providence, Rhode Island."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6753-7416","authenticated-orcid":false,"given":"Raymond","family":"Mager","sequence":"additional","affiliation":[{"name":"10AstraZeneca, Gaithersburg, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6144-6414","authenticated-orcid":false,"given":"Vicky","family":"Barnhart","sequence":"additional","affiliation":[{"name":"10AstraZeneca, Gaithersburg, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6074-8430","authenticated-orcid":false,"given":"Steven","family":"Eck","sequence":"additional","affiliation":[{"name":"10AstraZeneca, Gaithersburg, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1285-9238","authenticated-orcid":false,"given":"Elina","family":"Murtomaki","sequence":"additional","affiliation":[{"name":"11AstraZeneca, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2557-8170","authenticated-orcid":false,"given":"Ars\u00e8ne-Bienvenu","family":"Loemb\u00e9","sequence":"additional","affiliation":[{"name":"11AstraZeneca, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0077-3113","authenticated-orcid":false,"given":"Yun","family":"He","sequence":"additional","affiliation":[{"name":"12AstraZeneca, Waltham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1059-0940","authenticated-orcid":false,"given":"Zachary A.","family":"Cooper","sequence":"additional","affiliation":[{"name":"10AstraZeneca, Gaithersburg, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6174-8556","authenticated-orcid":false,"given":"Eric","family":"Tu","sequence":"additional","affiliation":[{"name":"10AstraZeneca, Gaithersburg, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9259-7064","authenticated-orcid":false,"given":"Chunling","family":"Fan","sequence":"additional","affiliation":[{"name":"10AstraZeneca, Gaithersburg, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8399-3152","authenticated-orcid":false,"given":"Agnes","family":"Boyer Chamard","sequence":"additional","affiliation":[{"name":"13Innate Pharma, Marseilles, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0780-3724","authenticated-orcid":false,"given":"Carine","family":"Paturel","sequence":"additional","affiliation":[{"name":"13Innate Pharma, Marseilles, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-0117","authenticated-orcid":false,"given":"Paula G.","family":"Fraenkel","sequence":"additional","affiliation":[{"name":"12AstraZeneca, Waltham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-7551","authenticated-orcid":false,"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[{"name":"5Gustave Roussy Cancer Center, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"2025092203015232900_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025092203015232900_bib2","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3389\/fimmu.2017.01526","article-title":"Multifaceted effects of extracellular adenosine triphosphate and adenosine in the tumor-host interaction and therapeutic perspectives","volume":"8","author":"de Andrade Mello","year":"2017","journal-title":"Front Immunol"},{"key":"2025092203015232900_bib3","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep"},{"key":"2025092203015232900_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting adenosine in cancer immunotherapy to enhance T-cell function","volume":"10","author":"Vigano","year":"2019","journal-title":"Front Immunol"},{"key":"2025092203015232900_bib5","doi-asserted-by":"crossref","first-page":"100302","DOI":"10.1016\/j.iotech.2022.100302","article-title":"190P Combination of IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: preclinical rationale","volume":"16","author":"Paturel","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"2025092203015232900_bib6","doi-asserted-by":"crossref","first-page":"118389","DOI":"10.1016\/j.lfs.2020.118389","article-title":"Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways","volume":"259","author":"Giatromanolaki","year":"2020","journal-title":"Life Sci"},{"key":"2025092203015232900_bib7","doi-asserted-by":"crossref","first-page":"G223","DOI":"10.1152\/ajpgi.00259.2006","article-title":"Upregulation of CD39\/NTPDases and P2 receptors in human pancreatic disease","volume":"292","author":"K\u00fcnzli","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"Suppl_16","key":"2025092203015232900_bib8","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1158\/1538-7445.AM2020-2152","article-title":"Abstract 2152: characterisation of co-expression of CD39 with other IO-relevant markers on major T\/NK cell TIL subsets","volume":"80","author":"Hair","year":"2020","journal-title":"Cancer Res"},{"key":"2025092203015232900_bib9","doi-asserted-by":"crossref","first-page":"S728","DOI":"10.1016\/j.annonc.2020.08.1193","article-title":"1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab \u00b1 oleclumab in advanced solid tumours","volume":"31","author":"Powderly","year":"2020","journal-title":"Ann Oncol"},{"key":"2025092203015232900_bib10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"2025092203015232900_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol Rev"},{"key":"2025092203015232900_bib12","doi-asserted-by":"crossref","first-page":"10453","DOI":"10.2147\/OTT.S272553","article-title":"High expression of CD39 is associated with poor prognosis and immune infiltrates in clear cell renal cell carcinoma","volume":"13","author":"Wu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"2025092203015232900_bib13","first-page":"P488","article-title":"IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, unleashes immune responses in combination with cancer therapies","volume":"7","author":"Andre","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025092203015232900_bib14","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2025092203015232900_bib15","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025092203015232900_bib16","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025092203015232900_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025092203015232900_bib18","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"2025092203015232900_bib19","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","article-title":"Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study","volume":"20","author":"Hui","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025092203015232900_bib20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4049\/immunohorizons.2200089","article-title":"SRF617 is a potent inhibitor of CD39 with immunomodulatory and antitumor properties","volume":"7","author":"Warren","year":"2023","journal-title":"Immunohorizons"},{"key":"2025092203015232900_bib21","doi-asserted-by":"crossref","first-page":"S1435","DOI":"10.1016\/j.annonc.2021.10.154","article-title":"135P First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors","volume":"32","author":"Patnaik","year":"2021","journal-title":"Ann Oncol"},{"key":"2025092203015232900_bib22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11883-014-0425-1","article-title":"CD39: interface between vascular thrombosis and inflammation","volume":"16","author":"Kanthi","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"2025092203015232900_bib23","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3390\/cells10092223","article-title":"Thrombo-inflammation: a focus on NTPDase1\/CD39","volume":"10","author":"Morello","year":"2021","journal-title":"Cells"},{"key":"2025092203015232900_bib24","doi-asserted-by":"crossref","first-page":"e000186","DOI":"10.1136\/jitc-2019-000186","article-title":"On the mechanism of anti-CD39 immune checkpoint therapy","volume":"8","author":"Allard","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025092203015232900_bib25","doi-asserted-by":"crossref","first-page":"633603","DOI":"10.3389\/fphar.2021.633603","article-title":"CD39 and CD73 as promising therapeutic targets: what could be the limitations?","volume":"12","author":"Battastini","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025092203015232900_bib26","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"2025092203015232900_bib27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pan.2017.04.012","article-title":"High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: a retrospective cohort study","volume":"17","author":"Berger","year":"2017","journal-title":"Pancreatology"},{"key":"2025092203015232900_bib28","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis","volume":"18","author":"Lyman","year":"2013","journal-title":"Oncologist"},{"key":"2025092203015232900_bib29","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"key":"2025092203015232900_bib30","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025092203015232900_bib31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-12-0789","article-title":"Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer","volume":"106","author":"Menapace","year":"2011","journal-title":"Thromb Haemost"},{"issue":"Suppl 12","key":"2025092203015232900_bib32","doi-asserted-by":"crossref","first-page":"CT011","DOI":"10.1158\/1538-7445.AM2022-CT011","article-title":"Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC)","volume":"82","author":"Cascone","year":"2022","journal-title":"Cancer Res"},{"key":"2025092203015232900_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/ajcp\/27.1.13","article-title":"Histochemistry of hepatic phosphatases of a physiologic pH; with special reference to the demonstration of bile canaliculi","volume":"27","author":"Wachstein","year":"1957","journal-title":"Am J Clin Pathol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0361\/3647950\/crc-25-0361.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1690\/3652985\/crc-25-0361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1690\/3652985\/crc-25-0361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:02:02Z","timestamp":1758524522000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/9\/1690\/765495\/IPH5201-an-Anti-CD39-mAb-as-Monotherapy-or-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0361","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30177688","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177700","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177721","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177724","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177712","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177697","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177730","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177718","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177709","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177715","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177703","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177706","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177727","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30177694","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8047519","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}